Further disease‐specific guidelines are currently in development through ClinGen and other curation networks, which incorporate additional disease‐associated features into variant classification; for example, loss of heterozygosity (LOH) and retention of a missense variant in a tumor would be informative for NF2 variant classification. This evidence concerns the gene NF2 and neoplasm.